Untangling the pharma patent puzzle
When it comes to patent protection in Brazil, it is fair to say that the pharmaceutical industry has faced more challenges than any other sector. During the past four decades, it has been necessary to overcome several obstacles, including the prohibition of patents in the pharmaceutical area and the conflict between the Brazilian Patent and Trademark Office (INPI) and the Brazilian Health Regulatory Agency (ANVISA), the entity corresponding to the US Food and Drug Administration.
